-
STAT News – Biotech2 weeks agoSTAT+: Eli Lilly and the ‘societal obligation’ of GLP-1s
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got more...
-
STAT News – Biotech2 weeks agoSTAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Hi there, and happy Wednesday from STAT’s London bureau, with Andrew Joseph here tag-teaming today’s edition with Mr. Pharmalot. We’re in the midst of those confusing...
-
Uncategorized2 weeks ago
11 Companies Hiring Now in New York
Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
-
STAT News – Biotech2 weeks agoHow to make emergency rooms safer for people with dementia
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Today’s the deadline for the White...
-
Uncategorized2 weeks ago
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiry of its...
-
Endpoints News2 weeks ago
Microneedle vaccine patch company raises $50M for pivot to GLP-1 delivery
Fourteen years ago, a group of Harvard Business School students launched a startup called Vaxess Technologies with a goal to disrupt the vaccine industry by replacing...
-
Uncategorized2 weeks agoNew protein drugs could pave way for faster drug development
A new class of protein drugs have shown amenability to multiple isotopes, paving the way for faster radiopharmaceutical drug development. Biotechnology company Molecular Partners announced preclinical...
-
BioPharma Dive – AI / Data2 weeks agoMerck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low purchase premium — which one analyst described as...
-
Uncategorized2 weeks agoGilead to advance first T cell engager for autoimmune diseases
Gilead Sciences has entered an agreement to acquire Ouro Medicines, a biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds...
-
Uncategorized2 weeks ago‘Supercharged’ T cells could improve prostate cancer treatment
Scientists have engineered new ‘supercharged’ immune cells that could attack prostate cancer more effectively. Researchers at UCLA and Stanford Medicine researchers, in collaboration with scientists from the...
